IL289585A - DLL3-targeted antibodies and uses thereof - Google Patents
DLL3-targeted antibodies and uses thereofInfo
- Publication number
- IL289585A IL289585A IL289585A IL28958522A IL289585A IL 289585 A IL289585 A IL 289585A IL 289585 A IL289585 A IL 289585A IL 28958522 A IL28958522 A IL 28958522A IL 289585 A IL289585 A IL 289585A
- Authority
- IL
- Israel
- Prior art keywords
- dll3
- targeting antibodies
- targeting
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872915P | 2019-07-11 | 2019-07-11 | |
| PCT/US2020/041282 WO2021007371A1 (en) | 2019-07-11 | 2020-07-08 | Dll3-targeting antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL289585A true IL289585A (en) | 2022-03-01 |
Family
ID=74115317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289585A IL289585A (en) | 2019-07-11 | 2022-01-03 | DLL3-targeted antibodies and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12441789B2 (https=) |
| EP (1) | EP3997127A4 (https=) |
| JP (2) | JP7661299B2 (https=) |
| KR (1) | KR20220034167A (https=) |
| CN (3) | CN119080930A (https=) |
| AU (1) | AU2020310894A1 (https=) |
| BR (1) | BR112022000216A2 (https=) |
| CA (1) | CA3146566A1 (https=) |
| CO (1) | CO2022001195A2 (https=) |
| IL (1) | IL289585A (https=) |
| MX (1) | MX2022000325A (https=) |
| PH (1) | PH12022550056A1 (https=) |
| WO (1) | WO2021007371A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2718257T3 (https=) * | 2014-05-30 | 2018-04-14 | ||
| CN119080930A (zh) * | 2019-07-11 | 2024-12-06 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
| CA3204628A1 (en) * | 2021-01-13 | 2022-07-21 | John T. POIRIER | Antibody-pyrrolobenzodiazepine derivative conjugate |
| MX2023008285A (es) * | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo anti-dll3-farmaco. |
| MX2023012614A (es) * | 2021-05-08 | 2023-11-03 | Shanghai Qilu Pharmaceutical Res And Development Centre Ltd | Molecula de union contra dll3 y uso de la misma. |
| AU2022339815A1 (en) * | 2021-09-02 | 2024-03-14 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting dll3 and uses thereof |
| WO2023034557A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof |
| JP2024534892A (ja) * | 2021-09-02 | 2024-09-26 | メモリアル スローン ケタリング キャンサー センター | 抗ｄｌｌ３抗体及びその使用 |
| CA3240378A1 (en) * | 2021-12-23 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody |
| EP4482859A1 (en) | 2022-02-27 | 2025-01-01 | Boehringer Ingelheim International GmbH | Bispecific antibodies against cd277 and a tumor-antigen |
| CN116003628A (zh) * | 2022-08-15 | 2023-04-25 | 南京博安生物技术有限公司 | 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用 |
| WO2025184421A1 (en) * | 2024-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1838968A (zh) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | 针对甲状旁腺激素(pth)之抗体和其用途 |
| AU2007325872B2 (en) * | 2006-11-08 | 2012-12-13 | Macrogenics West, Inc. | TES7 and antibodies that bind thereto |
| DK2530091T3 (en) | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
| WO2012013813A1 (en) | 2010-07-30 | 2012-02-02 | Gianluca Moroncini | Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof |
| NZ626242A (en) * | 2012-01-31 | 2017-02-24 | Regeneron Pharma | Anti-asic1 antibodies and uses thereof |
| BR112014020826A8 (pt) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| CA2939941A1 (en) | 2014-02-21 | 2015-08-27 | Abbvie Stemcentrx Llc | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| UY36245A (es) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| PT3221356T (pt) | 2014-11-20 | 2020-10-29 | Hoffmann La Roche | Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3 |
| CN119080930A (zh) * | 2019-07-11 | 2024-12-06 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
-
2020
- 2020-07-08 CN CN202411174923.9A patent/CN119080930A/zh active Pending
- 2020-07-08 BR BR112022000216A patent/BR112022000216A2/pt unknown
- 2020-07-08 AU AU2020310894A patent/AU2020310894A1/en active Pending
- 2020-07-08 MX MX2022000325A patent/MX2022000325A/es unknown
- 2020-07-08 WO PCT/US2020/041282 patent/WO2021007371A1/en not_active Ceased
- 2020-07-08 CN CN202411174926.2A patent/CN118955717A/zh active Pending
- 2020-07-08 EP EP20836805.0A patent/EP3997127A4/en active Pending
- 2020-07-08 CA CA3146566A patent/CA3146566A1/en active Pending
- 2020-07-08 US US17/622,404 patent/US12441789B2/en active Active
- 2020-07-08 JP JP2022501134A patent/JP7661299B2/ja active Active
- 2020-07-08 PH PH1/2022/550056A patent/PH12022550056A1/en unknown
- 2020-07-08 CN CN202080062231.9A patent/CN114341182B/zh active Active
- 2020-07-08 KR KR1020227004114A patent/KR20220034167A/ko active Pending
-
2022
- 2022-01-03 IL IL289585A patent/IL289585A/en unknown
- 2022-02-04 CO CONC2022/0001195A patent/CO2022001195A2/es unknown
-
2025
- 2025-04-02 JP JP2025061352A patent/JP2025156278A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114341182B (zh) | 2024-09-10 |
| JP2025156278A (ja) | 2025-10-14 |
| AU2020310894A1 (en) | 2022-02-03 |
| CA3146566A1 (en) | 2021-01-14 |
| JP2022540611A (ja) | 2022-09-16 |
| US20220348648A1 (en) | 2022-11-03 |
| EP3997127A1 (en) | 2022-05-18 |
| US12441789B2 (en) | 2025-10-14 |
| CN119080930A (zh) | 2024-12-06 |
| MX2022000325A (es) | 2022-03-25 |
| BR112022000216A2 (pt) | 2022-05-17 |
| CO2022001195A2 (es) | 2022-03-08 |
| KR20220034167A (ko) | 2022-03-17 |
| PH12022550056A1 (en) | 2023-04-12 |
| CN118955717A (zh) | 2024-11-15 |
| WO2021007371A1 (en) | 2021-01-14 |
| JP7661299B2 (ja) | 2025-04-14 |
| CN114341182A (zh) | 2022-04-12 |
| EP3997127A4 (en) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| IL275737A (en) | Variant antibodies against TIGIT | |
| IL289585A (en) | DLL3-targeted antibodies and uses thereof | |
| IL275826A (en) | Anti-mct1 antibodies and their uses | |
| ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
| SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| IL280321A (en) | Antibodies against CXCR2 and their uses | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL281202A (en) | Anti-TNFRSF9 antibodies and uses thereof | |
| ZA202100714B (en) | Anti-npr1 antibodies and uses thereof | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL289656A (en) | Anti-tigit antibodies and their application | |
| SG11202105161YA (en) | Anti-il-27 antibodies and uses thereof | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL283890A (en) | Anti-periostin antibodies and their uses | |
| ZA202210284B (en) | Anti-trem1 antibodies and related methods | |
| GB201902590D0 (en) | Antibodies and uses thereof | |
| IL288807A (en) | Anti-talen antibodies and their uses | |
| IL286285A (en) | Vista-binding antibodies and uses thereof |